| Literature DB >> 27829138 |
Lifeng Yang1, Abhinav Achreja1, Tsz-Lun Yeung2, Lingegowda S Mangala3, Dahai Jiang3, Cecil Han4, Joelle Baddour1, Juan C Marini5, Joseph Ni1, Ryuichi Nakahara1, Stephen Wahlig6, Lisa Chiba1, Sun Hye Kim1, Joshua Morse7, Sunila Pradeep3, Archana Sidalaghatta Nagaraja3, Monika Haemmerle3, Noh Kyunghee8, Mathew Derichsweiler1, Thomas Plackemeier1, Imelda Mercado-Uribe9, Gabriel Lopez-Berestein10, Tyler Moss11, Prahlad T Ram11, Jinsong Liu9, Xiongbin Lu4, Samuel C Mok2, Anil K Sood12, Deepak Nagrath13.
Abstract
Reactive stromal cells are an integral part of tumor microenvironment (TME) and interact with cancer cells to regulate their growth. Although targeting stromal cells could be a viable therapy to regulate the communication between TME and cancer cells, identification of stromal targets that make cancer cells vulnerable has remained challenging and elusive. Here, we identify a previously unrecognized mechanism whereby metabolism of reactive stromal cells is reprogrammed through an upregulated glutamine anabolic pathway. This dysfunctional stromal metabolism confers atypical metabolic flexibility and adaptive mechanisms in stromal cells, allowing them to harness carbon and nitrogen from noncanonical sources to synthesize glutamine in nutrient-deprived conditions existing in TME. Using an orthotopic mouse model for ovarian carcinoma, we find that co-targeting glutamine synthetase in stroma and glutaminase in cancer cells reduces tumor weight, nodules, and metastasis. We present a synthetic lethal approach to target tumor stroma and cancer cells simultaneously for desirable therapeutic outcomes.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27829138 PMCID: PMC7329194 DOI: 10.1016/j.cmet.2016.10.011
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287